SOURCE: Rheologics Technologies, Inc.

December 07, 2006 12:03 ET

Rheologics Establishes Scientific Advisory Board

EXTON, PA -- (MARKET WIRE) -- December 7, 2006 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that the Company has established its Scientific Advisory Board with the appointment of nine members, including the following cardiologists, hematologists, as well as pharmaceutical and bioengineering specialists:

Rodger L. Bick, MD, PhD, FACP

Since 1992, Dr. Bick has served as Clinical Professor of Medicine at the University of Texas Southwestern Medical Center. He is also Director of the Dallas Thrombosis Hemostasis & Vascular Medicine Clinical Center. Previously, he was Professor of Medicine at the UCLA Center for the Health Sciences, where he held a fellowship in Hematology and Medical Oncology. Prior to that, he completed an additional Coagulation Hematology Fellowship at the UC Irvine School of Medicine in affiliation with the Research Division of Hyland Laboratories. He was the founder and principal of ThromboCare Laboratories, a nationally recognized clinical testing facility for thrombosis-related disorders which was recently sold to a laboratory service company. Dr. Bick has published numerous journal articles and is the editor of the peer-review scientific journal Clinical and Applied Thrombosis/Hemostasis.

Anthony T. Cheung, PhD

Dr. Cheung is Professor Emeritus on Active Recall and Vice Chair for Research at the University of California-Davis School of Medicine. Since 1982, he has served on the faculty of the University of California-Davis School of Medicine as Professor of Clinical Pathology, Director of Biomedical Engineering Division and Chair of Advisory Research Committee of the Department of Medical Pathology and Laboratory Medicine. Dr. Cheung came to UC-Davis after serving at the California Institute of Technology for five years as a Research Scientist and Senior Fellow. Dr. Cheung is an Advisory Committee Member for an NIH consortium research grant -- "New Paradigms in the Design of Blood Substitutes" -- currently in place at Albert Einstein College of Medicine (Bronx, NY), University of California at San Diego (La Jolla, CA), and Carnegie Mellon University (Pittsburgh, PA). In addition, he serves as a reviewer of several scientific journals, has authored or co-authored over 100 scientific and clinical research papers, and has presented in over 100 national and international conferences.

Young I. Cho, PhD

Dr. Cho is Professor of Mechanical Engineering & Mechanics at Drexel University, where he has served as a member of the faculty since 1985. Dr. Cho initiated his research in blood viscometry as a member of the technical staff at NASA's Jet Propulsion Laboratory at the California Institute of Technology, where he was responsible for a range of experiments to determine the effect of space travel on the blood viscosity of astronauts. In 1986, Dr. Cho held a joint faculty appointment at the Argonne National Laboratory under the U.S. Department of Energy to develop a degradation-free non-Newtonian fluid. In 1993, he was nominated by the U.S. DoE and elected as the chairman of the Advanced Fluid Committee under the International Energy Agency. Dr. Cho has authored/co-authored approximately 150 papers in the area of heat transfer, fluid mechanics, rheology, aerodynamics, acoustics, combustion and energy and is a reviewer for a number of peer-review journals.

Gary C. Cupit, PharmD

Dr. Cupit is President of Enzo Therapeutics, Inc., a division of Enzo Biochem, Inc. Previously, he was President and CEO of Sapphire Therapeutics, a private biopharmaceutical company. Prior to Sapphire, Gary was Vice President, Global Business Development and Licensing, at Novartis. He has more than 20 years of pharmaceutical and healthcare industry experience in addition to 14 years in university-based academics and consulting in clinical pharmacy. Before Novartis, Gary held positions in Business Development at Knoll Pharmaceutical and was Vice President, Cardiovascular Business Unit (Angiomax®) with The Medicines Company of Cambridge, MA. Gary also held prior positions at SmithKline Beecham Pharmaceuticals in a number of capacities in sales (RMA), product management (Tagamet®, Hycamtin®) and new product development (Kytril®, Androderm®, Argatroban®). Prior to joining the pharmaceutical industry, Gary held faculty positions at New York Hospital-Cornell Medical Center, the University of California, San Francisco, the University of Pennsylvania and the University of Tennessee, Memphis. Gary earned his Bachelor of Science in Pharmacy from the Medical College of Virginia and Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.

Hau C. Kwaan, MD, PhD, FRCP, FACP

Dr. Kwaan is Professor of Medicine at the Division of Hematology and Oncology at Northwestern University, Feinberg School of Medicine, with a joint appointment as Attending Physician at the Northwestern Memorial Hospital in Chicago. His research focuses on thrombosis, fibrinolysis, hematology and vascular biology. From 1990-1995, Dr. Kwaan served on the editorial board of Thrombosis Research. Dr. Kwaan received his MD from the University of Hong Kong, with postgraduate medical training at the University of Edinburgh and the University of London, and a fellowship at Columbia University in New York City. He is a Fellow of the Royal College of Physicians of London and a founding member of the International Society of Thrombosis and Haemostasis. He is the recipient of numerous awards and honors. He is the author of over 300 journal articles and the editor of two medical textbooks: Thrombosis and Clinical Thrombosis.

Herbert J. Meiselman, ScD

Dr. Meiselman is Vice-Chair and Professor of Physiology and Biophysics at the University of Southern California Keck School of Medicine. For over 30 years, his research has focused on the science of blood flow in its various aspects, including but not limited to the effects of various pharmaceutical or biochemical interventions, in-depth analysis of the behavior of the components of blood, instrumentation and techniques for biophysical measurements including blood viscosity, and a wide variety of clinical studies related to blood flow and the biophysics of the blood. He is an author of over 200 peer-review journal articles and the editor of two textbooks: Erythrocyte Mechanics and Blood Flow and White Cell Mechanics: Basic Science and Clinical Aspects. Dr. Meiselman received his doctorate of science from the Massachusetts Institute of Technology in 1965, followed by a post-doctoral research fellowship at the California Institute of Technology.

Patrick Moriarty, MD, FACP, FACC

Dr. Moriarty is Associate Professor of Internal Medicine, Director of Clinical Pharmacology, Medical Director of Atherosclerosis and LDL-Apheresis Clinic at the University of Kansas Medical Center in Kansas City. He is one of the world's foremost authorities on LDL-apheresis, a procedure that filters the plasma resulting in an acute reduction reduces the level of LDL cholesterol, markers of inflammation, and blood rheology. His research interests include atherosclerosis, vascular inflammation, and blood rheology. He has completed over 75 clinical research studies as principal investigator or co-investigator. Research grants from the pharmaceutical industry involve hyperlipidemia, hypertension, diabetes, post-menopause, and obesity. He also participates in research related to LDL-apheresis and its potential use for congestive heart failure, acute coronary syndrome, retinal artery occlusion, and peripheral vascular disease. He has published extensively, sits on the editorial board of the Journal of Clinical Apheresis and Future Lipidology, and has successfully established his own clinic at the University of Kansas Medical Center for the treatment and prevention of vascular disease.

Robert S. Rosenson, MD, FACC, FACP, FAHA

He is Professor of Medicine and Director of Lipoprotein Disorders and Clinical Atherosclerosis Research / Cardiovascular Diseases at the University of Michigan in Ann Arbor. His clinical research has investigated the effects of lipid-lowering therapies, hypoglycemic therapies and antihypertensive agents on inflammation and thrombogenesis as well as the effects of hypolipidemic and antihypertensive agents on blood viscosity and fibrinogen. Previously, he was Professor of Cardiology at Northwestern University Medical School, where he also served as Director of the Preventive Cardiology Center and Director of the Lipoprotein and Hemorheology Research Facility. After receiving his medical degree from Tulane University, Dr. Rosenson completed his internship and residency at Brigham and Women's Hospital, Harvard Medical School, where he also held a Clinical Fellowship in Medicine. Following that, Dr. Rosenson completed his fellowship in cardiology at the University of Chicago. He has published over 70 peer-reviewed scientific papers and nearly 70 book chapters in the field. He also serves as an editor of a number of journals including Atherosclerosis.

Patrick L. Whitlow, MD

Dr. Whitlow is Director of Interventional Cardiology at The Cleveland Clinic Foundation, one of the world's preeminent heart centers. He also holds joint appointments at the Cleveland Clinic in the Departments of Cardiology, Vascular Medicine, and Molecular Cardiology. A leading interventional cardiologist, Dr. Whitlow has been responsible for conducting clinical studies using a broad range of device technologies including innovative angioplasties and stents as well as pharmaceutical therapeutics. He has been the principal investigator in over 40 clinical studies in this field of research and is currently the principal investigator in 8 active research studies at the Cleveland Clinic. He has published over 130 journal articles and numerous book chapters and monographs.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information